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Abstract
 
Tumors express embryonic carbohydrate antigens called tumor-associated carbohydrate antigens
(TACA). TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines
to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors,
rendering a vaccination strategy applicable in a large population. Here we demonstrate that by
using glycopeptides with high affinity for the major histocompatibility complex and glycosylated
in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce
anti-TACA CTL in vivo. In the current study we show that designer glycopeptides containing
the Thomsen-Freidenreich (TF) antigen (
 
 
 
-Gal-[1
 
→
 
3]-
 
 
 
-GalNAc-
 
O
 
-serine) are immunogenic
in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro
including a MUC1-expressing tumor. The fine specificity of the TF-specific CTL repertoire
indicates that the TcR recognize the glycosylated amino acid residue together with TF in a
conventional major histocompatibility complex class I–restricted fashion. These results have
high potential for immunotherapy against a broad range of tumors.
Key words: tumor-associated carbohydrate antigens • glycopeptides • CTL • 
carcinomas • immunotherapy
 
Introduction
 
A group of tumor-associated antigens that have been iden-
tified and characterized by virtue of their reactivity with
antibodies and lectins are carbohydrate in nature and called
tumor-associated carbohydrate antigens (TACA; 1). Numer-
ous studies indicate that some TACA are expressed on a va-
riety of neoplastic tissues (2–6) and not normally expressed
in differentiated cells, suggesting their suitability as a candidate
for vaccine therapy.
The crystal structure of human and murine T cell receptors
(TcRs) specific for immunodominant viral peptides presented
to cytotoxic T cell (CTL) suggests that the central region of
the peptide is critical for TcR contacts and that aromatic
rings are accommodated in a small cavity determined by
the variable CDR3 region of the TcR (7, 8). These data
suggest that small carbohydrate moieties may “fit” in the
variable region of the TcR. In fact, our preliminary studies
using trinitrophenyl (TNP) as a hapten model, suggested
that K
 
b
 
-restricted peptides haptenated in position 4 in 8
mers or position 5 in 9 mers induced a TNP-specific CTL
repertoire whose TcR was poorly dependent on MHC
class I contacts and highly degenerate (9). Because of these
encouraging results, we applied the same antigenic strategy
to TACA-containing glycopeptides because induction of a
degenerate T cell response against this class of tumor antigens
may be of great advantage in cancer immunotherapy (10–12).
The TACA-based vaccine candidates that we selected to
generate glycopeptides are the Thomsen-Freidenreich (TF)
antigen (
 
 
 
-Gal-[1
 
→
 
3]-
 
 
 
-GalNAc-
 
O
 
-serine) and its imme-
diate precursor Tn (GalNAc-
 
O
 
-serine; reference 13). TF is
expressed in different human carcinomas as a result of incom-
plete or aberrant glycosylation (14–18). In a systematic and
comparative immunohistochemical study it was shown that
the expression of TF and Tn was, with rare exceptions,
only found on neoplastic cells and not on normal tissue
(19). The importance of the TF antigen expression in carcino-
mas was also demonstrated by TF-specific antibody responses
in cancer patients (20). In fact, TF-specific mAbs have been
generated for prognostic and therapeutic applications (21–23).
The TF and Tn carbohydrate are also attractive candi-
dates for targeting immunotherapy against mucin (24), a
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polymorphic glycoprotein expressed by many epithelial-
derived carcinomas. Although interest has focused on de-
velopment of subunit vaccines against the core peptide unit
of mucin (25), the carbohydrate molecules associated with
mucin, which included TF and Tn (26), could also be con-
sidered for glycopeptides vaccine development. TF and Tn
represent neo antigens for T cell surveillance, as was shown
previously for humoral immunity against mucin (27).
In this paper we demonstrate that glycopeptides contain-
ing small TACA, a disaccharide and a monosaccharide
linked to a major TcR contact residue, and having high
binding affinity for MHC class I molecules, can serve as
vaccines that induce a degenerate carbohydrate-specific
CTL repertoire. Furthermore, our study also shows that
carbohydrate-specific CTL clones can recognize tumor
cells of different origin that express TACA in the context
of endogenous glycopeptides of unknown sequences.
These findings support the value of the carbohydrate vac-
cine approach for cancer prevention and treatment.
 
Materials and Methods
 
Mice.
 
Female C57BL/6 mice (6–12 wk old) were purchased
from The Jackson ImmunoResearch Laboratories.
 
Peptides and Glycopeptides.
 
The peptides used in this study
were synthesized by Fmoc chemistry using a multiple peptide syn-
thesizer (Symphony/Multiplex; Protein Technologies). Peptides
were cleaved automatically on the synthesizer using trifluoracetic
acid as a cleavage reagent. Peptides were 
 
 
 
97% pure as assessed by
C18 reverse phase high performance liquid chromatography, and
the identity of the peptides was verified by mass spectroscopy. De-
signer alanine-rich peptides with the appropriate MHC anchor
and a natural sequence from the Sendai virus NP 324–332
(FAPGNYPAL), modified in position 5 (N
 
→
 
S), were used for
carbohydrate conjugation. The designer peptide is a 9-mer that
contained the major anchor residues phenylalanine (F) in position
6 and leucine (L) in position 9, together with isoleucine (I) at posi-
tions 2 and 3, which we defined to be important for binding to K
 
b
 
molecules. The glycopeptides containing TF (
 
 
 
-Gal-[1
 
→
 
3]-
 
 
 
-
GalNAc-
 
O
 
-serine) and Tn (GalNAc-
 
O
 
-serine) used in this study
were prepared at Carlsberg Laboratories by solid phase synthesis
using glycosylated amino acids as building blocks, as described pre-
viously (28). Glycopeptides were 
 
 
 
97% pure as assessed by C18
reverse phase high performance liquid chromatography, and the
identity of the peptides was verified by mass spectroscopy.
 
MHC Binding Assay.
 
EL-4 cells were used as a source of K
 
b
 
molecules. Nonidet P-40 cell lysates from large scale (10
 
9
 
–10
 
11
 
)
cell cultures were filtered through 0.45-
 
 
 
m filters and purified by
affinity chromatography. To measure peptide binding to MHC
molecules, MHC binding peptides identified previously were 
 
125
 
I
radiolabeled and incubated with 5–10 nM of purified MHC mole-
cules for 48 h in PBS containing 0.05% Nonidet P-40 and protease
inhibitors. The K
 
b
 
 binding complexes were subsequently separated
from free peptide by gel filtration TSK columns. The binding ca-
pacity of peptides to K
 
b
 
 molecules was measured by their capacity
to inhibit binding of the radiolabeled ligand. The affinity of the
binding was estimated by determining the quantity of peptide re-
quired to inhibit 50% of the binding of the radiolabeled peptide.
 
Immunization Protocols and Characterization of CTL Lines and
Clones.
 
Glycopeptides were emulsified in incomplete Freund ad-
juvant and injected subcutaneously at the concentration of 50 
 
 
 
g,
together with 140 
 
 
 
g of an IA
 
b
 
-restricted Th epitope, the hepatitis
B virus core antigen sequence 128–140 (TPPAYRPPNAPIL; 9).
Mice were killed 7 d after priming. Splenocytes from each experi-
mental group were pooled and stimulated in vitro in the presence
of the glycopeptide that was used as immunogen and, as an APC
source, irradiated syngeneic B cell blasts activated in vitro for 48 h
by culturing splenocytes with LPS (from 
 
Salmonella typhosa
 
: Sigma-
Aldrich) and dextran sulfate (Amersham Biosciences). Culture me-
dium consisted of RPMI 1640 (Life Technologies) supplemented
with 20 mM glutamine, 100 
 
 
 
g streptomycin, 100 U/ml penicil-
lin, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids
(Life Technologies), 50 
 
 
 
M 2-ME, and 10% heat-inactivated FCS
(Life Technologies). After 5 d in culture, cells were collected, pu-
rified over Ficoll gradients, and T cell blasts were cultured in com-
plete RPMI conditioned with supernatant from Con A (Sigma-
Aldrich)–activated splenocytes as an IL-2 source. 2 d later (day 7 in
culture) T cells were tested for CTL activity. Carbohydrate and
peptide specificity were studied in a standard 
 
51
 
Cr release assay us-
ing the lymphoma EL-4 (H-2
 
b
 
) cell line as targets at different E/T
in duplicate, with and without antigens. Net specific lysis has been
calculated by subtracting the cytolytic response to EL-4 cells in the
absence of glycopeptides or peptides defined as background. Data
were calculated as % cytotoxicity 
 
 
 
 [(sample 
 
  
 
spontaneous re-
lease)/(maximum release 
 
 
 
 spontaneous release)] 
 
  
 
100.
T cell clones were generated from selected TACA-specific
CTL lines at 6 to 7 d after a single in vitro stimulation with the
immunizing glycopeptide to avoid in vitro selection. In brief, after
Ficoll purification, T cell blasts were plated in 96-well U-bottom
plates at 0.5 cell/well in the presence of 1 
 
 
 
g/ml glycopeptide
and irradiated LPS/dextran sulfate–activated B cell blasts. Grow-
ing wells were expanded with Con A supernatant and restimu-
lated with irradiated B cell blasts and glycopeptide. CTL clones
were tested for specificity by using EL-4 targets. Endogenous rec-
ognition of the carbohydrate expressed by tumor cells was deter-
mined using as targets for the 
 
51
 
Cr release assay the mammary tu-
mor lines TA3/Ha, a well-characterized tumor line known for
TF expression, which has been used by other investigators in car-
bohydrate-based immunotherapeutic studies (3, 29) and TA3/
Ha/K
 
b
 
, the ovary tumor lines MM14 (American Tissue Culture
Collection) and MM14/K
 
b
 
. The melanoma cell line B16 trans-
fected with the human MUC1 gene, namely B16/MUC1 (30),
was also included in the study.
 
Results
 
Generation of a Peptide Backbone Suitable for Carbohydrate
Conjugation.
 
There is a very strong correlation between
the affinity of peptide binding to MHC molecules and the
capacity of the peptide to induce an immune response (31,
32). This information is critical to the strategy used in this
study. The size of a peptide determines its capacity to bind
class I MHC. Whereas the optimal peptide length for most
murine MHC molecules appears to be 9-amino acid resi-
dues, the K
 
b
 
 and K
 
k
 
 molecules prefer 8-residue peptides (33).
K
 
b
 
 molecules were initially chosen to define a glycopeptide
that: (a) binds with high affinity; and (b) will be of a structure
that skews the T cell response toward recognition of the car-
bohydrate moiety rather than toward either the peptide or
the MHC molecule. The critical anchor residues for K
 
b
 
binding have been canonically defined as phenylalanine (F)
or tyrosine (Y) in position 5 and leucine (L) or methionine 
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(M) at position 8 of an octamer peptide (8). The mainte-
nance of critical hydrogen bonding between main chain at-
oms in the peptide and atoms in the MHC molecules can be
theoretically accomplished with any natural-occurring
l-amino acid, avoiding detrimental residues at nonanchor
positions that interfere with the “docking” of peptides in the
MHC binding groove. Detrimental amino acids tend to be
negatively or positively charged amino acids, or in some in-
stances, proline (34, 35). On this basis, alanine (A)-, serine
(S)-, and glycine (G)-rich peptides were synthesized, each
containing the anchor of phenylalanine (F) in position 5 and
leucine (L) in position 8 and their ability to bind to K
 
b
 
 was
measured (36). The quantity of peptide needed to achieve
50% inhibition of binding of a reference peptide approxi-
mates the affinity of interaction (
 
k
 
D
 
) between the peptide
and MHC. There was considerable difference in the capacity
of these anchor residue–containing peptides with different
peptide backbones to bind to the K
 
b
 
 molecule as shown in
Table I. The glycine-rich peptide bound with very low af-
finity (53 
 
 
 
M), whereas the serine-rich peptide had 
 
 
 
100-
fold higher affinity. The alanine-rich peptide showed the
highest affinity for K
 
b
 
 molecules, with a 50% inhibition of 75
nM. On this basis, alanine was chosen as the most appropri-
ate amino acid residue to be used in the peptide backbone
for carbohydrate conjugation. Crystallographic analysis of
peptides bound to the K
 
b
 
 molecule demonstrated an inter-
esting difference between the conformation of an 8-mer
peptide bound to K
 
b
 
 versus a 9-mer peptide (8, 34). Peptides
with 8 amino acids had been previously shown to be the op-
timal length, and the crystallographic analysis indicated that
in order for a 9-mer peptide to be accommodated in the
peptide binding groove, the first anchor residue had to be
shifted from residue 5 to residue 6, thus creating a “bulge” in
the NH
 
2
 
-terminal region of the peptide between residues 1
and 6. It was considered possible that this bulge created to
accommodate a 9-mer peptide might be a useful location to
attach a carbohydrate residue, to enhance the hapten speci-
ficity of the CTL response. For this reason, we identified
9-mer peptides that could bind to K
 
b
 
 with high affinity. In-
creasing the length of the alanine-rich peptide from 8- to
9-amino acid residues resulted in eightfold reduction in the
affinity for K
 
b
 
 molecules from 75 to 610 nM (Table I). To
improve this affinity we added isoleucine (I) at position 2
and/or position 3 as previous studies had indicated that these
positions might be capable of engaging secondary binding
pockets in the MHC molecule (35). High affinity binding
(Table I, 10 nM) was achieved when isoleucines were in-
serted at positions 2 and 3. More significantly, further modi-
fication of the peptide with the TF or Tn carbohydrate
linked with serine in position 5 (relevant for TcR contact in
the K
 
b
 
 model; reference 8) did not alter this high affinity
binding (Table I, lines 8–10). Thus, this alanine-rich 9-mer
peptide sequence conjugated with TF or Tn through a
serine in position 5 was chosen for further studies.
 
Generation of Anti-TACA CTL In Vivo.
 
To generate
anti-TACA–specific CTL, the 9-mer alanine-rich peptides
conjugated with either the TF antigen (
 
 
 
-Gal-[1
 
→
 
3]-
 
 
 
-
GalNAc-
 
O
 
-serine) or the monomeric Tn (GalNAc-
 
O
 
-
serine) were tested as vaccines in vivo. C57BL/6 mice (H-
2
 
b
 
) were coimmunized subcutaneously with 50 
 
 
 
g CTL
glycopeptide and a potent Th epitope (9) in incomplete
Freund adjuvant. Mice were killed 7 d after priming and
splenocytes were restimulated in vitro with the glycopep-
tide immunogen. Irradiated, LPS/dextran sulfate–activated
B cell blasts were used as APC in culture after pulsing for
2 h with glycopeptides (50 
 
 
 
g/10 
 
 
 
 10
 
6
 
 cells). CTL lines
were expanded with Con A supernatant as an IL-2 source
after separation by Ficoll gradient at day 5 in culture. This
protocol is very efficient in generating antigen-specific mu-
rine CD3
 
 
 
 CD8
 
 
 
 T cells in vitro inasmuch as CD8
 
 
 
 T
cells represent 
 
 
 
75% of the total population at day 7 in
culture. Moreover, lack of exogenous IL-2 for such a pro-
longed time limits considerably the expansion of nonspe-
cific T cells.
T cell cultures were tested for CTL activity after 7 d in
culture in a standard 
 
51
 
Cr release assay. The well-character-
ized thymoma cell line EL-4 (H-2
 
b
 
) was used as target cells
as they do not express MHC class II molecules, thus avoid-
ing false interpretation of the results due to contaminating
CD4
 
 
 
 T cells. Moreover, EL-4 cells do not endogenously
synthesize TF, as shown in the left panel of Fig. 4.
Carbohydrate specificity was investigated by comparing
the response between the glycopepeptide and its respective
nonglycosylated counterpart. As shown in Fig. 1, strong
CTL activity specific for the immunizing glycopeptide was
generated by either the TF- (Fig. 1 A) or the Tn-(Fig. 1 B)
containing glycopeptide(s). In contrast, greatly diminished
activity was observed against the same peptide in a nongly-
cosylated form, demonstrating the generation of carbohy-
 
Table I.
 
Construction of High Affinity K
 
b
 
 Binding Peptide 
Backbones for Carbohydrate Conjugation
 
Peptide
K
 
b
 
 binding 
capacity IC
 
50
 
nM
 
1. GGGGFGGL 53,000
  2. SSSSFSSL 509
  3. AAAAFAAL 75
  4. AAAAAFAAL 610
  5. AIAAAFAAL 240
  6. AAIAAFAAL 90
  7. AIIAAFAAL 10
  8. AIIASFAAL 4
  9. AIIA(
 
 
 
Gal-[1
 
→
 
3]-
 
 
 
-GalNAc-
 
O
 
-ser)FAAL 4
10. AIIA(GalNac-
 
O
 
-ser)FAAL 4
Glycine-, serine-, and arginine-rich peptides with relevant K
 
b
 
 anchor
positions were compared for their capacity to bind to purified K
 
b
 
molecules. K
 
b
 
 binding was measured as the quantity of peptide required
to inhibit by 50% (IC
 
50
 
) the binding of a well-characterized
radioiodinated K
 
b
 
 binding peptide. 
Glycopeptide-based Cancer Immunotherapy
 
710
drate-specific CTLs that either do not use TcR contacts
within the peptide backbone or are not activated if such
contacts exist. The study has been extended to a large
number of mice immunized with the TF-containing glyco-
peptide. 30 out of 45 analyzed (67%) generated a TF-spe-
cific CTL repertoire whereas 13 (29%) generated a reper-
toire that was carbohydrate specific but cross-reactive to
the peptide backbone. None of the animals generated a
CTL response that was exclusively peptide specific and two
mice (4%) failed to respond to vaccination. Mice were con-
sidered responders if their TF-specific recognition at 10:1
E/T ratio was 
 
 
 
15% after subtracting nonglycosylated
peptide recognition and nonspecific lysis (cytolytic activity
in the absence of antigen).
 
Cross-Reactivity between TACA-specific CTL Responses.
 
Carbohydrate chains expressed on the cell surface of tumor
cells increase in length during synthesis and modifications
in the glycan group may be recognized in a cross-reactive
fashion by CTL or they may be recognized as antagonist or
null antigens (37). As those possibilities have implications in
the design of carbohydrate-based immunotherapeutic vac-
cines, the reciprocal cross-reactivity between primary CTL
lines generated with the disaccharide TF antigen and the
Figure 1. Specificity of primary CTL cell cultures tested in a 51Cr
release assay. Labeled EL-4 cells (H-2b) were incubated with different
cell number of T cell blasts in the presence of 1  g/ml of the immuno-
gen glycopeptide or the unglycosylated peptide backbone. EL-4 cells
plated with T cell blasts in the absence of antigens have been assessed in
duplicate at every E/T ratio to determine the extent of nonspecific lysis.
Cell cultures supernatants were harvested 4 h later and percent 51Cr
released was calculated as (sample   spontaneous release)/(maximum
release   spontaneous release)   100. Background lysis has been sub-
tracted and net lysis is shown. Open symbols represent carbohydrate
specificity and filled symbols represent peptide specificity. (A) Primary
CTL response in a mouse primed with TF ( -Gal-[1→3]- -GalNAc-
O-ser). (B) Primary CTL response in a mouse primed with Tn (Gal-
NAc-O-ser).
Figure 2. Cross-reactivity between TF and Tn. Splenocytes from
immunized mice were pooled in a representative experiment. (A) Average
CTL response in 10 mice primed with the TF-serine glycopeptide (filled
circles) and the cross-reactive response to Tn (filled squares). (B) Average
CTL response of 10 mice primed with the Tn-serine glycopeptide (filled
squares) and the cross-reactive response to TF (filled circles). Open symbols
represent the specific response to the peptide backbone (AIIASFAAL) in
both groups. The background has been subtracted and net lysis is shown.Xu et al. 711
monosaccharide Tn antigen conjugated to the alanine-rich
nonapeptide was examined.
The results indicate that mice immunized with the TF-
conjugated glycopeptide generated a CTL repertoire that
cross-reacted with Tn (Fig. 2 A). Reciprocally, CTL lines
from Tn-immunized mice cross-reacted with TF (Fig. 2 B).
The results suggest that the GalNAc moiety is highly immu-
nogenic and is recognized by the large majority of the T cell
receptors. Differences in the magnitude of the CTL cross-
reactive response to Tn by the TF-specific T cells suggest
that TcR fine specificities include T cells whose fine speci-
ficity is driven toward the  -Gal or the disaccharide  -Gal-
(1→3)- -GalNAc (Fig. 2 A). Similarly, differences in the
magnitude of the CTL cross-reactive response to TF by Tn-
specific T cells suggest that some Tn-specific TcRs cannot
accommodate two glycan groups, although the large major-
ity of the T cells recognize the GalNAc moiety as was the
case for cells primed with TF (Fig. 2 B).
Taken together the results suggest that Tn is highly im-
munogenic. Moreover, the higher magnitude of the pri-
mary CTL response to the Tn-containing glycopeptide
compared with the TF-containing glycopeptides may re-
flect better presentation of the carbohydrate molecule to
TcRs due to its smaller size and reduced flexibility when
bonded to Kb molecules.
Immunogenicity of TF Conjugated to Different Amino Acid
Linkers. To determine the effect of the amino acid linkers
on induction of carbohydrate-specific CTLs, we generated
two new TF-containing glycopeptides where instead of
serine, bulkier lysine and ornithine residues were chosen
for glycosylation in order to enhance the protrusion of the
carbohydrate toward the solvent (28). When mice were
immunized with TF linked by lysine or ornithine, CTL re-
sponses were observed although as shown in Fig. 3, the re-
sponses induced by both glycopeptides were skewed to-
ward recognition of the peptide backbone rather than the
carbohydrate moiety. These results were somewhat surpris-
ing and contrast our previous findings with a different hap-
ten model (9). Overall these results indicate that glycopep-
tides containing TF linked via a serine residue are the best
candidates for immunotherapy.
Recognition of TF-expressing Tumors by Glycopeptide-specific
CTL Clones. The recognition of TF-expressing tumor
cells by CTL generated from vaccination with the TF-con-
jugated glycopeptides represents a critical test for the dis-
ease relevance of designer glycopeptide-based vaccines.
TF-specific CTL clones were generated from indepen-
dent T cell lines derived from mice immunized with the
TF-serine–containing glycopeptides that were stimulated
once in vitro with the glycopeptide immunogen. The T
cell clonal repertoire derived from these mice was highly
specific for the carbohydrate moiety, supporting results ob-
tained with primary T cell lines.
The T cell clones were tested in vitro for their ability to
recognize tumor cells that endogenously synthesize the car-
bohydrate antigen. Three tumor cell lines have been se-
lected as targets for these experiments: (a) a well-character-
ized mammary carcinoma that expresses TF, namely TA3/
Ha (3, 29); (b) the MM14 ovary carcinoma that also ex-
presses TF, as determined by anti-TF mAbs staining (pro-
vided by Dr. B. Jansson, Bioinvent Therapeutic AB, Lund,
Sweden; reference 3) the B16 melanoma cell line (H-2b)
transfected with the human MUC1 gene, designated as
B16/MUC1 (30). The glycoprotein MUC1 contains TF as
determined in our laboratory by specific mAbs staining and
reported in the literature (26). The TF expression of these
tumors has been evaluated by FACS® analysis using anti-TF
mAbs provided by Dr. B. Jansson (38). As shown in the left
panel in Fig. 4, the thymoma cell line EL-4 used as target
for glycopeptide-specificity studies does not express TF en-
dogenously. However, the mammary carcinoma TA3/Ha
and the ovary carcinoma MM14 showed very high TF ex-
Figure 3. Immunogenicity of glycopeptides containing TF conjugated
to lysine or ornithine at position 5. TF-lysine (A) and TF-ornithine (B)
were tested and compared for their ability to generate TF-specific CTL.
The primary CTL response in six mice primed with each glycopeptide is
shown (spleens pooled). The CTL response to the immunizing glycopeptide
is represented by open symbols, and the CTL response to the respective
peptide backbone is represented by filled symbols in both panels. The back-
ground has been subtracted and net lysis is shown.Glycopeptide-based Cancer Immunotherapy 712
pression, representing ideal targets to evaluate the ability of
glycopeptide-generated CTL to recognize tumors in vitro.
Moreover, the melanoma cell line B16 may be induced to
express TF when transfected with the MUC1 gene, how-
ever, the expression was lower compared with carcinomas
as shown in the right panel in Fig. 4.
The two carcinomas cell lines TA3/Ha and MM14 were
transfected with a Kb plasmid (donated by Dr. S. Joyce,
Vanderbilt University School of Medicine, Nashville, TN)
to provide the appropriate MHC class I allele for CTL rec-
ognition. Parental cell lines (H-2a) were also included as
control in the same assays to determine the MHC restric-
tion of the CTL clonal repertoire.
The three representative CTL clones shown previously
that responded to tumor cells generated from mice primed
with the  -Gal-(1→3)- -GalNAc-O-serine glycopeptide
showed cytotoxic activity against the TA3/Ha/Kb mam-
mary tumor line transfected with Kb molecules and the Kb-
transfected MM14/Kb ovary tumor line but not against the
parental tumor lines that expressed the antigen but were
MHC class I mismatched. These findings indicate that TF-
specific CTL can recognize the TACA endogenously ex-
pressed in a MHC class I–dependent fashion (Fig. 5 A). In
support of these results, the same T cell clones were also
capable of recognizing the melanoma cell line B16 (synge-
neic with the T cells) transfected with the MUC1 gene
(B16/MUC1) but not the TACA-negative parental cell
line (Fig. 5 B). The lysis of this tumor was reduced com-
pared with the two carcinomas cell lines. A possible expla-
nation is the lower expression of TF molecules on B16/
MUC1 cell surface compared with the two epithelial tu-
mors as shown in Fig. 4.
Fine Specificity of TF-specific CTL Clones. In the next
series of experiments the fine specificity of TF-serine–spe-
cific CTL clones was analyzed to address the importance of
the glycosylated amino acid linker for TcR recognition.
CTLs were tested for their cross-reactivity to TF-lysine,
TF-ornithine, and TF-homoserine (hs). TF-hs glycopep-
tides were included in this analysis because they were
shown previously to be highly immunogenic and capable
of inducing helper-independent T cell responses (39).
Lastly, we determined the exclusive relevance of position
5 for TcR contact that is critical for the degeneracy of the
Figure 4. TF expression by different tumor cell lines. IgM TF1 mAb and anti–IgM-FITC have been used in these experiments where the isotype
control is also shown.
Figure 5. Endogenous recognition of TF-specific CTL clones. (A) Three
representative TF-specific T cell clones recognize Kb-transfected carcinomas
that express TF, but not the parental tumor lines H-2 mismatched (H-2a).
(B) B16 melanoma (H-2b) transfected with the MUC1 gene is also recog-
nized by the same T cell clones, but not the parental cell line lacking the
TACA antigen (SD  1.5 in three repeated experiments).Xu et al. 713
T cell repertoire. Degeneracy is an important consideration
for carbohydrate vaccines as the endogenous peptide pre-
senting TACA in cancer patients is unknown.
We addressed this question by testing the cross-reactivity
of TF-specific CTL clones against an unrelated glycopep-
tide generated from the Sendai virus NP 324–332 epitope
sequence that contained TF conjugated at position 5 via
substituted serine residue (5N→5TF-S). Previous studies
have shown that position 5 of this epitope is a critical TcR
contact site (8).
TF-specific T cell clones showed high affinity/avidity
for the TF-serine glycopeptides as shown in Fig. 6. How-
ever, the results of the cross-reactivity of the T cell clones
against glycopeptides carrying different linkers were sur-
prising because TF-serine–specific CTL clones did not
cross-react either with the TF-hs–containing glycopeptide,
or with the lysine- or ornithine-containing glycopeptides
regardless of the concentration. These findings indicate that
TF-specific TcRs recognize the natural amino acid linker
in the immunogen together with the sugar moiety (Fig. 6).
Similarly, none of 45 TF-hs–specific T cell clones derived
from mice primed with the TF-hs–linked glycopeptide
were capable of recognizing the TF-serine glycopeptides or
tumor cells expressing TF (unpublished data).
However, T cell clones showed good cytolitic activity in
response to the glycopeptide FAPG(TF-S)YPAL derived
from Sendai NP 324–332 (Fig. 6), supporting the impor-
tance of the core of the peptide (position 5 in a 9-mer) for
TcR contacts and the high degeneracy of the TACA-spe-
cific CTL repertoire in immunized mice that generated a
TF-specific CTL response (67% out of 45 studied).
Discussion
Here we report that it is possible to generate CTL
against two very well-known tumor-associated carbohy-
drate antigens largely expressed in a variety of epithelial tu-
mors, TF and Tn, by using as vaccines designer glycopep-
tides with high affinity for MHC class I molecules. The
results in the current study are very encouraging because
TACA-containing glycopeptides glycosylated in a critical
position for TcR recognition to a natural amino acid linker
(serine) generated a carbohydrate-specific CTL clonal rep-
ertoire in vivo that recognize TACA endogenously ex-
pressed in a MHC class I–restricted fashion. We believe
that this vaccine approach is particularly interesting for can-
cer prevention because: (a) TACA are expressed very early
during neoplastic transformation (1) rendering possible im-
munosurveillance by CTL (40); (b) the same TACA-based
vaccine can be used in a variety of tumors, circumventing
the limitation of epitope mapping; and (c) by designing ap-
propriate peptide(s) backbone sequence(s) it may be possi-
ble to target multiple supertype MHC class I alleles (36, 41)
and a variety of cancer types, rendering feasible future
CTL-based vaccines applicable on a large population scale.
In support of this approach is also the fact that the carbohy-
drate-specific T cell repertoire generated by designer pep-
tide backbones for hapten conjugation is highly degenerate,
Figure 6. Fine specificity of TF-specific CTL clones. The fine specificity
of three representative CTL clones that recognize TF endogenously ex-
pressed on tumor cells have been characterized by studying the cross-reactiv-
ity to TF-hs–, TF-lysine–, and TF-ornithine–glycopeptides. A modified viral
natural sequence from the Sendai virus carrying TF linked to serine in posi-
tion 5 (5N→5TF-S) was also tested in these experiments (E/T ratio of 5:1).Glycopeptide-based Cancer Immunotherapy 714
as indicated by the recognition of tumors that express
the TACA antigen in the context of unknown endoge-
nous peptides and the recognition of a different se-
quence carrying the carbohydrate antigen in the same
position. Degeneracy of the CTL repertoire has been re-
ported previously in a different hapten model relevant in
allergy (9), suggesting that hapten-specific CTL may be
successfully targeted for different immunotherapeutic
approaches.
MHC-restricted, carbohydrate-specific CTL have been
generated in different viral models, indicating that peptides
can be posttranscriptionally glycosylated once they are
loaded in the binding groove of the MHC class I molecule
(42–46). One study that characterized the immunogenicity
of designer glycopeptides modified a TcR contact(s) within
a viral epitope described the induction of non-MHC class
I–restricted CTL (47). In another study in allergic patients,
pollen carbohydrate–specific CTL have been also detected
(48). Altogether, these findings indicate that carbohydrate-
specific CD8  T cells are represented in secondary lym-
phoid organs and may critically contribute to native im-
mune responses.
The idea of targeting glycoproteins for cancer immuno-
therapy has been pioneered by Dr. O. J. Finn and her
group (for review see reference 25), initially from the ob-
servation that human epithelial cells express on the cell sur-
face a polymorphic epithelial mucin, which is encoded by
the MUC1 gene, developmentally regulated and aberrantly
expressed in tumors (49). Mucin is recognized by CTL in
breast and pancreatic cancer (50), as well as by CTL that
infiltrate ovarian malignant tumors (51). The highly repeti-
tive sequence of the polypeptide core in mucin may allow
simultaneous recognition of many identical epitopes and
cross-linking by TcRs (50). A phase I clinical trial in ade-
nocarcinoma patients that were vaccinated with a 105–
amino acid synthetic mucin MUC1 peptide that has five
repeated immunodominant epitopes demonstrated that an-
timucin CTL were detectable in 7 out of 22 patients (52).
It is worth considering that  25% of the amino acids
within the mucin sequence are serine or threonine (49),
potential  O-glycosylation sites, suggesting that carbohy-
drate molecules may be as relevant tumor antigens for CTL
as they are for humoral responses (27). The data here re-
ported suggest that a glycosylated version of this peptide
may be used as a vaccine to potentially increase immuno-
genicity and antitumor efficacy of the CTL repertoire.
Moreover, complex carbohydrates are not removed during
processing of glycoproteins by dendritic cells and MUC-1
glycopeptides are presented to MHC class II–restricted T
helper cells (53). MUC1-specific T helper cells cross-
reacted with TF and Tn, contained within the MUC1 gly-
coprotein (53) suggesting that either CD4  or CD8  T
cells accommodate small sugar moiety in their TcRs that
represent optimal target for T cell–based immunotherapy.
This hypothesis will be explored in the near future in a
spontaneous mammary tumor model (MUC1/MMT),
which is ideal to test the ability of glycopeptides to prevent
or delay tumor onset.
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